



## PRELIMINARY SCORE

### CURATIVE



### NON-CURATIVE



## ADJUSTMENTS

### Quality of life



### Serious and disabling adverse effects



### Other adjustments



## FINAL SCORE

### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

### NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

### INFORMATION

Tumour type: Skin Cancers

Therapeutic Indication: EMA: Indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease. FDA: Indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.

Experimental Arm: Talimogene Laherparepvec

Control Arm: Subcutaneous granulocyte macrophage colony-stimulating factor (GM-CSF)

